SNSE insider trading
NasdaqCM HealthcareSensei Biotherapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Company website: www.senseibio.com
SNSE insider activity at a glance
FilingIQ tracks 265 insider transactions for SNSE in filings since Feb 10, 2021. The most recent transaction is dated Jun 1, 2026.
Across the full history, 159 open-market purchases
and 51 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SNSE insider trades is 51.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SNSE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SNSE?
- FilingIQ tracks 265 Form 4 insider transactions for SNSE (Sensei Biotherapeutics, Inc.), covering filings from Feb 10, 2021 onwards. 0 of those are dated within the last 90 days.
- Are SNSE insiders net buyers or net sellers?
- Across the full Form 4 history for SNSE, 159 transactions (60%) were open-market purchases and 51 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SNSE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is SNSE in?
- Sensei Biotherapeutics, Inc. (SNSE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $43.96M.
Methodology & sources
Every SNSE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.